If your prescription says DOTATATE — not DOTANOC — this page explains why the distinction matters, when DOTATATE is the specific tracer your oncologist or nuclear medicine physician has chosen, the critical connection between Ga-68 DOTATATE PET CT and Lu-177 DOTATATE therapy, and what it costs in Delhi.
DOTATATE PET CT scan cost in Delhi ranges from ₹18,000 to ₹25,000 at AERB-licensed nuclear medicine centres — the same price range as DOTANOC at equivalent quality centres.
DOTATATE vs DOTANOC — The Clinical Distinction
This is the most important section on this page. DOTATATE and DOTANOC are not interchangeable.
Both Ga-68 DOTATATE and Ga-68 DOTANOC share a quite similar somatostatin receptor binding profile. However, the in vitro affinity of Ga-68 DOTATATE in binding somatostatin receptor subtype 2 (SST2) is approximately 10-fold higher than that of DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is SST2 that is predominantly overexpressed in NETs. International Journal of Reproduction, Contraception, Obstetrics and Gynecology
Ga-68 DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5. It has a wider receptor binding profile than Ga-68 DOTATATE, which is SST2-selective. The wider receptor binding profile might be advantageous for imaging because neuroendocrine tumours express different subtypes of somatostatin receptors. Jammi Scans
The practical clinical distinction:
|
Feature |
Ga-68 DOTATATE |
Ga-68 DOTANOC |
|
Somatostatin receptor targets |
SST2 — selective |
SST2, SST3, SST5 — broader |
|
SST2 affinity |
~10-fold higher than DOTATOC |
High but lower than DOTATATE for SST2 |
|
Primary clinical advantage |
SST2-expressing NETs — highest uptake |
NETs with SST3 and SST5 expression in addition |
|
Lu-177 DOTATATE companion diagnostic |
Standard companion |
Also used but DOTATATE is the matched tracer |
|
Availability in India |
Select AERB-licensed centres |
More widely available |
The booking rule: If your prescription specifically says DOTATATE — do not accept DOTANOC as a substitute without confirming with your oncologist. If you are being assessed for Lu-177 DOTATATE therapy (LUTATHERA) specifically — DOTATATE is the appropriate companion diagnostic.
What DOTATATE PET CT Is Used For
Neuroendocrine Tumour Staging and Restaging
DOTATATE PET CT is used for the same primary NET indications as DOTANOC:
- Initial staging of well-differentiated neuroendocrine tumours (Grade 1 and 2)
- Restaging after surgery, chemotherapy, or PRRT
- Identification of the primary tumour when a NET metastasis has been found and the primary site is unknown
- Whole body mapping of somatostatin receptor-expressing disease before treatment planning
Which NETs respond best to DOTATATE imaging: Gastroenteropancreatic NETs (GEP-NETs) — carcinoid tumours of the small intestine, pancreatic NETs, gastrinomas, and most well-differentiated NETs — express SST2 at high levels. These tumours are well-imaged by DOTATATE.
Before Lu-177 DOTATATE Therapy — The Most Critical Indication
This is the clinical context where DOTATATE (specifically, rather than DOTANOC) is the most important investigation.
The receptor expression can be demonstrated by PET imaging before the patient is treated. The first commercially available product Lu-177-DOTATATE was approved following the NETTER-1 trial — demonstrating a median progression-free survival of 28.4 months compared to 8.5 months for octreotide LAR in G1 and G2 gastrointestinal NETs. Southerngem
Lu-177 DOTATATE (Lutetium-177 DOTATATE, brand name LUTATHERA) is a peptide receptor radionuclide therapy (PRRT) for metastatic well-differentiated NETs. It uses a DOTATATE molecule labelled with the beta-emitting isotope Lutetium-177 — which binds to SST2 receptors on NET cells and delivers targeted radiation directly to them.
Why Ga-68 DOTATATE PET CT is required before Lu-177 DOTATATE therapy:
The diagnostic Ga-68 DOTATATE PET CT and the therapeutic Lu-177 DOTATATE use the same molecular vector (DOTATATE) — one labelled for imaging (Gallium-68), the other for therapy (Lutetium-177). This is the theranostic principle — the diagnostic scan confirms that tumour cells will take up the therapeutic agent before treatment begins.
What the pre-PRRT scan confirms:
- Adequate SST2 expression across disease sites — confirming the tumour will take up Lu-177 DOTATATE
- Full disease mapping before treatment — all sites that should respond to therapy
- Baseline for post-treatment response assessment
The clinical consequence of this theranostic link: A patient whose DOTATATE PET CT shows high and uniform DOTATATE uptake across all metastatic sites will have a strong treatment response to Lu-177 DOTATATE. A patient with low or heterogeneous uptake may not respond — and the therapeutic PRRT can be reconsidered.
Note on DOTANOC for PRRT candidacy assessment: DOTANOC PET CT can also be used for PRRT candidacy assessment in most centres because it maps the same somatostatin receptor landscape. Your nuclear medicine physician and oncologist will confirm which tracer is required at your specific PRRT centre.
What DOTATATE PET CT Shows — The Specific Findings
Lesion detection in NETs: Ga-68 DOTATATE maps somatostatin receptor expression in all NET lesions throughout the body — primary tumour, lymph node metastases, liver metastases, bone metastases, and lung metastases. Well-differentiated Grade 1 and 2 NETs typically show very high DOTATATE uptake (high SUVmax) because they express abundant SST2.
The grade correlation: Grade 1 NETs — highest DOTATATE uptake, typically very bright on scan. Grade 2 NETs — high to moderate uptake. Grade 3 NETs / poorly differentiated NECCs — may have low DOTATATE uptake and may be better imaged with FDG PET CT.
The dual tracer principle for aggressive NETs: In Grade 3 or aggressive NETs, your oncologist may order both DOTATATE PET CT (to map SST2 expression) and FDG PET CT (to map glucose metabolism). Sites positive on DOTATATE are suitable for PRRT. Sites positive only on FDG (DOTATATE-negative) represent more aggressive, dedifferentiated disease that requires chemotherapy rather than PRRT.
DOTATATE PET CT vs DOTANOC PET CT — Which Does Your Oncologist Need?
For most clinical situations in India, DOTANOC and DOTATATE produce equivalent clinical information for NET staging and restaging. The choice between them is determined by:
Choose DOTATATE specifically when:
- You are being evaluated specifically for Lu-177 DOTATATE (LUTATHERA) therapy — the matched theranostic pair
- Your nuclear medicine centre or PRRT centre specifically requires DOTATATE for their pre-PRRT protocol
- Your oncologist has explicitly written DOTATATE on the prescription
DOTANOC is acceptable when:
- Initial NET staging and no specific PRRT evaluation planned
- Your nuclear medicine centre has more reliable DOTANOC supply
- Your oncologist has written DOTANOC or "somatostatin receptor PET CT" without specifying the tracer
The practical guidance: If your prescription says DOTATATE and you are being assessed for PRRT — book DOTATATE specifically. If your prescription says DOTANOC or does not specify between the two — confirm with your oncologist or nuclear medicine physician before booking. EVE Healthcare confirms the specific tracer required before any DOTATATE or DOTANOC appointment is confirmed.
The Critical Preparation — Somatostatin Analogue Pause
This is the same critical preparation step as DOTANOC — but stated here explicitly because DOTATATE patients may not have seen the DOTANOC preparation guide.
If you are on long-acting somatostatin analogues — octreotide LAR (Sandostatin LAR) or lanreotide (Somatuline) — these must be paused before your DOTATATE PET CT.
<br>
Long-acting somatostatin analogues compete with the Ga-68 DOTATATE tracer for SST2 receptor binding. A patient who receives DOTATATE PET CT while still on octreotide LAR gets a significantly degraded scan — tumour lesions may appear less intense or even invisible because the receptor sites are already occupied by the therapeutic analogue.
The pause duration:
- Long-acting formulations (octreotide LAR, lanreotide): Pause for 4–6 weeks before the scan
- Short-acting octreotide (subcutaneous): Pause for 24 hours before the scan
- Confirm the exact pause duration with your oncologist — do not pause independently
This pause must be arranged before booking. If your next octreotide LAR injection is in 3 weeks, book your DOTATATE PET CT for at least 4 weeks after the last injection — not 3 weeks. The scheduling must account for the full pause window.
Day of scan:
- Fast for 4–6 hours
- Drink water generously
- Continue all other medications unless specifically told otherwise
DOTATATE PET CT Cost in Delhi 2026
|
Option |
Cost (₹) |
Waiting Time |
|
AERB-licensed standalone nuclear medicine centre |
18,000 – 25,000 |
3–7 days advance booking |
|
Private hospital nuclear medicine department |
28,000 – 42,000 |
3–7 days |
|
Government centre (AIIMS, Tata Memorial equivalent) |
8,000 – 15,000 |
Variable waiting list |
|
CGHS rate (NABH) |
17,000 |
Confirm empanelment |
Availability note: Ga-68 DOTATATE requires advance tracer supply planning — typically 3–7 days advance booking at EVE partner centres. When booking, state specifically: "Ga-68 DOTATATE PET CT" — not just "DOTANOC" or "somatostatin receptor PET."
DOTATATE PET CT Near Me — Delhi NCR
|
Area |
Availability |
Price Range |
Metro |
|
South Delhi (Green Park, Safdarjung, Saket) |
Select AERB centres |
₹18,000 – ₹25,000 |
Yellow / Violet |
|
Central Delhi (Karol Bagh) |
Select AERB centres |
₹18,000 – ₹25,000 |
Blue / Yellow |
|
North Delhi (Rohini) |
Select |
₹18,000 – ₹22,000 |
Red Line |
|
Noida (Sector 62, 125) |
Select |
₹18,000 – ₹22,000 |
Blue Line |
|
Gurgaon (Golf Course, Sector 38) |
Select |
₹18,000 – ₹25,000 |
Yellow Line |
Clinical Note
From the reviewing nuclear medicine physician: The DOTATATE vs DOTANOC question comes up at least weekly in my Delhi practice. For most NET patients being staged or restaged without a specific PRRT plan — DOTANOC and DOTATATE are clinically equivalent and either is acceptable. The distinction becomes clinically critical in the theranostic context: if a patient is being evaluated for Lu-177 DOTATATE therapy, the companion diagnostic should be Ga-68 DOTATATE because the imaging tracer and the therapeutic agent use the same molecular vector. Using DOTANOC for pre-PRRT imaging and then treating with Lu-177 DOTATATE is not necessarily wrong — but DOTATATE provides the most direct predictive mapping because it targets the same receptor with the same peptide as the therapy. The preparation instruction I emphasise most for DOTATATE patients — identical to DOTANOC — is the somatostatin analogue pause. A patient on octreotide LAR who books their DOTATATE PET CT 2 weeks after their last injection (instead of 4–6 weeks) is getting a scan where the receptor sites are still partially occupied. The scan quality is degraded. The pre-PRRT assessment is compromised. Four to six weeks is the window — plan the booking date backwards from that requirement.
Book Your DOTATATE PET CT in Delhi
Tell our team: "Ga-68 DOTATATE PET CT" and whether this is for NET staging or pre-PRRT assessment. Share your prescription. We confirm tracer availability and that the octreotide pause requirement has been arranged before booking.
Also see: DOTANOC PET CT Scan Cost Delhi → · FDG vs PSMA vs DOTANOC vs DOPA → · How to Prepare for PET CT → · PET CT Scan Cost Delhi → · CGHS PET CT Rate Delhi